[go: up one dir, main page]

WO2003018010A1 - Preventive and/or remedial agent for disease attributable to arteriosclerotic activity - Google Patents

Preventive and/or remedial agent for disease attributable to arteriosclerotic activity Download PDF

Info

Publication number
WO2003018010A1
WO2003018010A1 PCT/JP2002/008398 JP0208398W WO03018010A1 WO 2003018010 A1 WO2003018010 A1 WO 2003018010A1 JP 0208398 W JP0208398 W JP 0208398W WO 03018010 A1 WO03018010 A1 WO 03018010A1
Authority
WO
WIPO (PCT)
Prior art keywords
preventive
arteriosclerotic activity
arteriosclerotic
activity
remedy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008398
Other languages
English (en)
French (fr)
Inventor
Shinichi Ishii
Kazuyo Sasaki
Hiroaki Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Priority to CA002457836A priority Critical patent/CA2457836A1/en
Priority to US10/487,492 priority patent/US20040198774A1/en
Priority to JP2003522528A priority patent/JPWO2003018010A1/ja
Priority to EP02762812A priority patent/EP1419771A4/en
Publication of WO2003018010A1 publication Critical patent/WO2003018010A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2002/008398 2001-08-23 2002-08-21 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity Ceased WO2003018010A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002457836A CA2457836A1 (en) 2001-08-23 2002-08-21 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
US10/487,492 US20040198774A1 (en) 2001-08-23 2002-08-21 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
JP2003522528A JPWO2003018010A1 (ja) 2001-08-23 2002-08-21 動脈硬化作用に基づく疾患の予防及び／または治療薬
EP02762812A EP1419771A4 (en) 2001-08-23 2002-08-21 AGENTS FOR THE PREVENTION AND / OR TREATMENT OF DISEASES THAT ARE ATTRIBUTED TO ARTERIOSCLEROTIC EFFECT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001252388 2001-08-23
JP2001-252388 2001-08-23

Publications (1)

Publication Number Publication Date
WO2003018010A1 true WO2003018010A1 (en) 2003-03-06

Family

ID=19080872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008398 Ceased WO2003018010A1 (en) 2001-08-23 2002-08-21 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity

Country Status (5)

Country Link
US (1) US20040198774A1 (ja)
EP (1) EP1419771A4 (ja)
JP (1) JPWO2003018010A1 (ja)
CA (1) CA2457836A1 (ja)
WO (1) WO2003018010A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604983A1 (en) * 1992-12-28 1994-07-06 Mitsubishi Chemical Corporation Naphthalene derivatives
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO2000078312A1 (en) * 1999-06-18 2000-12-28 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2002013812A1 (en) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
EP1088824B1 (en) * 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604983A1 (en) * 1992-12-28 1994-07-06 Mitsubishi Chemical Corporation Naphthalene derivatives
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO2000078312A1 (en) * 1999-06-18 2000-12-28 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2002013812A1 (en) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACKSON SIMON M. ET AL.: "Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction", ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 9, 1999, pages 2094 - 2104, XP001004723 *
REGINATO MAURICIO J. ET AL.: "A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties", J. BIOL. CHEM., vol. 273, no. 49, 1998, pages 32679 - 32684, XP002960280 *
ZHU LINGYU ET AL.: "9-cis Retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells", ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 9, 1999, pages 2105 - 2111, XP002960281 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Also Published As

Publication number Publication date
US20040198774A1 (en) 2004-10-07
EP1419771A1 (en) 2004-05-19
EP1419771A4 (en) 2004-11-03
JPWO2003018010A1 (ja) 2004-12-09
CA2457836A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
EP1213296A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING SAID DERIVATIVES AND INTERMEDIATE PRODUCTS OBTAINED DURING THEIR PRODUCTION
MXPA04002035A (es) Derivados de 1, 8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
EP1550662A4 (en) NEW ADENINE COMPOUND AND ITS USE
IL139227A0 (en) N-substituted aminotetralins as ligands for the neuropeptide yy5 receptor useful in the treatment of obesity and other disorders
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
NO20062509L (no) Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
WO2003018010A1 (en) Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
MXPA03008134A (es) Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion.
CA2370244A1 (en) Piperidine derivatives
CA2336412A1 (en) Medicament for treatment of diabetes
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
WO2004028455A3 (en) Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
FI872930A0 (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
CA2373395A1 (en) Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DE60013560D1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
JPH1087492A (ja) 一酸化窒素産生阻害剤
MXPA01007705A (es) Derivado de benzamida y medicamento que lo contiene.
NO20070421L (no) Radiosensitiviserende middel
WO2000048447A3 (en) Composition for treatment of external secretion disorders except hypolacrimation
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003522528

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2457836

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002762812

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10487492

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002762812

Country of ref document: EP